(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 3, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall impact of rheumatologic diseases from more than 40 abstracts, including three oral presentations, will be presented at the 2015 American College of Rheumatology (ACR) Annual Meeting, Nov. 7-11, in San Francisco. These data reinforce AbbVie's continued leadership in immunology and commitment to those living with a variety of inflammatory diseases. 'As a leader in delivering medicines to address unmet needs in immune-mediated disorders, we are highlighting scientific insights...
↧